BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ('BioNxt' or the 'Company') (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report on several major milestones for the next 90 days, including the registration of national-level patents, the completion of a human bioequivalence study for its lead Multiple Sclerosis (MS) treatment, and the development of its longevity and anti-aging product.
Global Patent Filings: Accelerating Commercial Pathways for BioNxt's Pipeline
BioNxt confirm that all national-level filings pursuant to the Patent Cooperation Treaty (PCT) are complete in key jurisdictions of interest, including the United States, Canada, Australia, Europe, and Japan. The Company's national-level filings are based on the positive international examination report issued by the European Patent Office (EPO) in Q3 2024 for the Company's comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, such as MS. The Company is working to accelerate the processing and registration of national-level patents with updates to be provided as they develop.
Securing nation-level patents in premier pharmaceutical markets around the globe is a central milestone for BioNxt and will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
Human Bioequivalence Study for Lead Multiple Sclerosis Product
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence to existing oral therapies, with plans underway to commence the first clinical trial in the next 90 days. The bioequivalence study is relatively short and scheduled for less than 30 days from start to finish.
Successful completion of the Company's sublingual Cladribine bioequivalence study is a major milestone for the Company and a proof-of-concept demonstration for BioNxt's lead product and its pipeline of sublingual products targeting autoimmune diseases.
Expansion into Longevity and Anti-Aging
In the next 90 days, BioNxt plans to enter the rapidly growing longevity and anti-aging sector, projected to reach $93-billion (U.S.) by 2027 (Statista). The company is advancing proprietary sublingual (thin-film) and oral (enteric-coated tablet) drug products with active pharmaceutical ingredients that show early-stage evidence of benefits such as slowing ovarian aging, extending fertility and promoting healthy aging. These innovative solutions are tailored to meet the growing demand for effective anti-aging therapies.
The Company's longevity and anti-aging programs represent a strategic and diversified investment in a large and rapidly growing global market. BioNxt looks forward to providing further details in the coming weeks.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange:BNXT, OTC Markets:BNXTF and trades in Germany under WKN:A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Phone: +1 778.598.2698
Cautionary Statement Regarding 'Forward-Looking' Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
9 hours ago
- Indianapolis Star
New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
This week's episode is sponsored by The Sustainable Green Team's Waterless Garden (OTC:SGTM) and PetVivo Holdings, Inc.'s (NASDAQ:PETV) innovative SPRYNG™ product. NEW YORK CITY, NY / ACCESS Newswire / June 14, 2025 / New to The Street, the nationally syndicated business television series known for spotlighting innovation across sectors, announces the premiere of Episode #671 airing tonight on Bloomberg Television at 6:30 PM EST. This week's broadcast features five dynamic companies making waves across blockchain, AI, health tech, wellness, and pharmaceutical sectors: FLOKI – The globally recognized crypto and blockchain brand building Web3 utility through its DeFi ecosystem. Arrive AI (NASDAQ:ARAI) – Developer of a patented smart mailbox delivery platform, leading last-mile logistics innovation with its autonomous, AI-powered systems. Health In Tech (NASDAQ:HIT) – A pioneer in digital underwriting and quote-to-card technology for health insurance, transforming how plans are built and priced. Vita Bella – A wellness brand that continues to expand its national presence through health-focused lifestyle offerings. NRX Pharmaceuticals (NASDAQ:NRXP) – A late-stage pharmaceutical company advancing treatments for CNS disorders and respiratory distress. This week's featured corporate sponsors include: The Sustainable Green Team (OTC:SGTM) and its revolutionary Waterless Garden initiative for drought-resistant, sustainable landscaping. PetVivo Holdings, Inc. (NASDAQ:PETV), showcasing continued progress with its SPRYNG™, a veterinary injectable device for treating osteoarthritis in companion animals. Upcoming Highlights: New to The Street has also wrapped filming this week with several prominent brands: GLINT Pay (Private) – A disruptive gold-as-money platform allowing real-time gold transactions. Lahontan Gold Corp. (TSX.V:LG / OTCQB:LGCXF) – Canadian gold exploration company with high-grade assets in Nevada. Greer Consulting Group – Providing strategic solutions across regulatory compliance, M&A, and executive strategy. Special Feature Segment: A culinary showcase from two of New York City's most iconic dining destinations – Black Barn and Hunt & Fish Club – blending luxury hospitality with the business of restaurant branding. Additionally, special segments fromIMG Academy, Skip Barber Racing School, and KITON will continue to roll out in the coming months as part of New to The Street's ongoing coverage of elite performance, luxury, and innovation. Quote from Vince Caruso, Creator and Executive Producer of New to The Street: 'We continue to be a destination for innovative and publicly traded companies ready to tell their story at scale. Tonight's show blends AI, healthcare, crypto, and wellness with real national TV exposure. We're proud to feature these brands and grateful to our show sponsors for helping amplify their messages.' About New to The Street Since 2009, New to The Street has become one of the most trusted platforms for public and private companies to share their stories. The show combines sponsored programming with earned media, enhanced by iconic outdoor campaigns, nationwide TV commercials, and non-deal roadshows that connect executives with top-tier investors and institutions. With weekly reach across 220 million linear TV households, a growing 2.65 million YouTube subscribers, and a robust social media presence exceeding 700,000 followers across LinkedIn, Facebook, Instagram, and X, New to The Street delivers unparalleled exposure and credibility in the business media space. For more information, visit SOURCE: New To The Street View the original press release on ACCESS Newswire
Yahoo
11 hours ago
- Yahoo
Sturm Ruger CEO sees 2025 bottom line impacted by price repositioning moves
On June 13, Sturm, Ruger & Company provided a communication from Todd Seyfert, CEO, to its employees regarding his first 100 days and management's ongoing corporate strategy initiatives, the company disclosed in a regulatory filing. In the letter to employees, Seyfert stated in part: 'The last few months have been nothing short of transformative – and it's thanks to your focus, dedication, and belief in what we're building. As I have been doing since my first days as CEO, I wanted to update you all transparently and clearly about where I see our short-term and long-term future… With these bold moves, there comes a cost – both emotionally and financially. Change of this scale requires tough decisions, meaningful investment, and short-term impacts that we've chosen to take head-on to position Ruger for long-term strength… It is important to note that we are making these strategic decisions now – thoughtfully and intentionally – so that Ruger is positioned for consistency, stability, and profitable growth in 2026 and beyond. Yet, there will be a cost to the Company for 2025. We expect the expense-related to these initiatives to total approximately $15 million to $20 million over the remainder of the year. We additionally anticipate our price repositioning moves to impact our overall bottom line over that same period. Consequently, we currently believe that our results for the remainder of the year, before the one-time costs and expenses, will look more like prior periods, such as the latter part of 2019, where the Company continued to focus on executing its long-term strategy and delivering long-term value for shareholders in the face of broader industry challenges. These actions will be largely completed by the beginning of 2026, placing Ruger in a strong position for renewed growth and performance in the years to come. Importantly, none of this will slow our momentum when it comes to investing in what matters most, including aggressive new product development and expansion of capacity in areas where market demand exceeds our current ability to supply. We remain fully committed to profitable expansion, product innovation, agile responsiveness, and ensuring we meet the expectations of our customers and the marketplace.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RGR: Disclaimer & DisclosureReport an Issue Sturm Ruger Announces Strategic Initiatives Under New CEO Supreme Court blocks Mexico suit against gunmakers Sturm Ruger Appoints New General Counsel Sturm Ruger Amends By-Laws for Shareholder Actions Sturm Ruger Reports Stable Q1 2025 Financial Results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
Chanson International prices 16M units at 50c in public offering
Chanson International (CHSN) has priced a best-efforts public offering with gross proceeds to the Company expected to be approximately $8M, before deducting placement agent fees and other estimated expenses payable by the Company, excluding the exercise of any warrant offered. The offering is comprised of 16,000,000 units, consisting of one Class A ordinary share of the Company, par value $0.001 per share, or in lieu thereof, a pre-funded warrant, one series A warrant to purchase one Class A Ordinary Share and one series B warrant to purchase one Class A Ordinary Share. The public offering price of the Units is $0.50 per Unit. Each of the Series A Warrants and the Series B Warrants will have an exercise price of $0.525 per Class A Ordinary Share and be exercisable beginning on the date of the issuance date and ending on the two and half anniversary of the issuance date. The offering is expected to close on or about June 16, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to open new stores in China and in the U.S., and the specific allocation of net proceeds to each market will be based on market conditions. Univest Securities is acting as sole placement agent for the offering. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CHSN: Disclaimer & DisclosureReport an Issue Chanson International files to sell 25M units on 'best-efforts basis' Chanson International Innovates with New Natural Sweetener Blend Chanson International announces self-developed 'Songkang Meal' series Chanson reports on diversity initiatives, responsible business practices Chanson International announces new formulation for sugar Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
